PAYS Paysign, Inc.

CIK 0001496443 41 ready 8-Ks latest August 5, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 41

Latest filing August 5, 2026, 4:05 PM ET

Top materiality 0.90

Event mix earnings ×20 · other ×8 · other_material ×7

Sentiment 19 pos · 0 neg · 22 neu

Latest earnings ▲ beat 2025-Q3

Executive change recent →

Recent 8-K filings for PAYS

Highest-materiality recent filing

Paysign Reports FY2024 Revenue of $58.38M and Acquires Gamma Innovation Assets

March 25, 2025, 7:59 PM ET M&A materiality 0.90 positive item 2.02 item 3.02 item 7.01 item 9.01

Full-year 2024 total revenues increased 23.5% to $58.38 million, with pharma patient affordability revenue up 214.5%.
Full-year 2024 net income was $3.82 million ($0.07 per diluted share), down from $6.46 million in 2023 due to prior year tax benefit.

Read filing →

August 5, 2026, 4:05 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Paysign reports record Q2 revenue $28.3M (+48%), raises FY2026 outlook

Revenue $28.25M, up 48.1% YoY; GAAP net income $6.76M ($0.11 EPS) vs $1.39M ($0.02) prior year.
May 12, 2026, 4:05 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M

Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).
March 24, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Paysign FY2025 revenue $82.0M (+40.5%); guides FY2026 revenue $106.5-110.5M, net income nearly doubles

Full-year 2025 total revenues $82.0M (up 40.5% YoY); net income $7.55M ($0.13 diluted EPS) vs $3.82M ($0.07) in 2024.
November 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Paysign Q3 revenue $21.6M (+41.6% YoY); raises full-year 2025 guidance

Q3 2025 revenue $21.6M (+41.6% YoY); net income $2.22M (+54.2% YoY); diluted EPS $0.04 vs $0.03 YoY.
September 16, 2025, 7:59 PM ET litigation materiality 0.65 neutral item 7.01 item 9.01

Paysign proposes settlement of four derivative actions; court hearing set for Nov 14, 2025

Settlement resolves four stockholder derivative actions alleging violations of Exchange Act and fiduciary duties.
August 5, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Paysign Q2 revenue $19.08M (+33%), net income $1.39M (+99%), raises FY2025 guidance

Q2 revenue $19.08M (+33.1% YoY), net income $1.39M (+99.1%), diluted EPS $0.02; Adj. EBITDA $4.51M (+101.8%), $0.08 per share.
May 8, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance

Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.
March 25, 2025, 7:59 PM ET M&A materiality 0.90 positive item 2.02 item 3.02 item 7.01 item 9.01

Paysign Reports FY2024 Revenue of $58.38M and Acquires Gamma Innovation Assets

Full-year 2024 total revenues increased 23.5% to $58.38 million, with pharma patient affordability revenue up 214.5%.
November 5, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Paysign Q3 revenue up 23% to $15.26M; pharma affordability revenue surges 219%

Total revenues $15.26M (+23% YoY); net income $1.44M ($0.03 diluted EPS) vs $1.10M ($0.02) prior year.
July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance

Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.
May 7, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q1 revenue $13.2M (+30% YoY); net income $309k vs loss; reaffirms FY guidance

Total revenue $13.2M, up 30% YoY; net income $309k ($0.01 diluted EPS) vs net loss $160k in Q1 2023.
April 19, 2024, 7:59 PM ET litigation materiality 0.65 neutral item 8.01

Court approves $3.75M settlement of Paysign securities class action; claims dismissed

U.S. District Court for Nevada granted final approval of settlement on April 17, 2024.
March 26, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign FY2023 revenue up 24% to $47.3M; net income $6.5M; guides FY2024 revenue $54.5-56.7M

Full-year 2023 total revenue $47.3M (+24% YoY); net income $6.5M ($0.12 diluted EPS) vs $1.0M ($0.02) in 2022.
November 7, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q3 revenue up 17% to $12.4M; net income $1.1M; pharma revenue +142%

Q3 total revenues $12.4M (+17% YoY); net income $1.1M, diluted EPS $0.02.
August 8, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q2 revenue up 28% to $11.0M; Adjusted EBITDA $1.1M; guides FY rev $44-46M

Revenue $11.0M, up 28% YoY; net loss $0.1M ($0.00 EPS).
May 10, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q1 rev +23% to $10.1M, net loss narrows; Q2 guidance calls for continued growth

Q1 2023 revenues $10.1M (+23% YoY); net loss $0.2M improved from $0.3M loss a year ago.
March 22, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Paysign reports FY2022 revenue $38.0M (+29% YoY), net income $1.0M; guides FY2023 revenue $44-46M

Full-year 2022 revenue $38.0M, up 29% YoY; net income $1.0M ($0.02 diluted EPS) vs net loss of $2.7M in 2021.
November 8, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Paysign Q3 2022 revenue $10.6M (+36% YoY); net income $0.85M; guides FY2022 rev $38.15-38.35M

Revenue $10.6M (+36% YoY); net income $0.85M vs loss of $0.27M in Q3 2021; diluted EPS $0.02.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Paysign Q2 revenue $8.6M (+29% YoY); net loss narrows to $0.2M; adds 62 plasma centers

Revenue $8.6M, up 29% YoY; net loss $0.2M vs $0.7M loss last year; adjusted EBITDA $0.9M.
May 11, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Paysign Q1 revenue $8.2M (+31% YoY), net loss $0.3M; reaffirms FY2022 guidance

Revenue $8.2M vs $6.3M in Q1 2021; net loss $0.3M (($0.01) per share).
March 22, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Paysign Q4 2021 rev $8.8M, net income $0.1M; FY22 guidance rev $35.3-38.4M

Q4 total rev $8.8M (+21% YoY); net income $0.1M vs loss; adj EBITDA $1.3M.
November 9, 2021, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Paysign Q3 revenue $7.8M; plasma $7.0M (+35.6% YoY); net loss $0.3M; raises adj. EBITDA guidance to $1.3-1.9M

Total revenue $7.8M for Q3 2021, up $1.1M (16.8%) from Q2 2021 and $7.9M from year-ago.
August 10, 2021, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Paysign Q2 2021 revenue $6.7M (+3.2% YoY); net loss $0.9M; raises adjusted EBITDA guidance

Q2 revenue $6.7M (+3.2% YoY); net loss $0.9M (($0.02) diluted EPS).

Executive changes

Appointed

Cosimo Cambi

Chief Operating Officer

PAYS · Paysign, Inc.

Effective: 2024-01-24
Filed: January 29, 2024, 6:59 PM ET

Paysign, Inc. (the “Company”) appointed Cosimo Cambi as Chief Operating Officer of the Company

Role change

Mark Newcomer

President

PAYS · Paysign, Inc.

Effective: 2024-01-24
Filed: January 29, 2024, 6:59 PM ET

the Company re-appointed Mr. Mark Newcomer as President, succeeding Mr. Lanford

Role change

Matt Lanford

Chief Payments Officer

PAYS · Paysign, Inc.

Effective: 2024-01-24
Filed: January 29, 2024, 6:59 PM ET

Mr. Matt Lanford, who was appointed as Chief Payments Officer effective as of the same date.

Appointed

Matt Lanford

director

PAYS · Paysign, Inc.

Effective: 2022-08-08
Filed: August 9, 2022, 7:59 PM ET

the Board appointed Matt Lanford as a director of the Company.

Departed

Daniel H. Spence

member of the Board of Directors

PAYS · Paysign, Inc.

Effective: 2022-08-08
Successor: Matt Lanford
Filed: August 9, 2022, 7:59 PM ET

Mr. Daniel H. Spence resigned as a member of the Board of Directors (the “Board”) of Paysign, Inc. (the “Company”), effective August 8, 2022.

Departed

Daniel H. Spence

Executive Vice President

PAYS · Paysign, Inc.

Effective: 2021-09-30
Filed: October 6, 2021, 7:59 PM ET

On September 30, 2021, Paysign, Inc. (the “Company”) and Mr. Daniel H. Spence, Executive Vice President, agreed that Mr. Spence’s employment with the Company would end, effective September 30, 2021.

Earnings & guidance

2025-Q3 EPS reported $0.10 vs consensus $0.02 ▲ beat (+390.2%) filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

19 positive 0 negative 22 neutral

source · PAYS on sec.gov